1998
DOI: 10.3109/17453679809117611
|View full text |Cite
|
Sign up to set email alerts
|

Decreased levels of IGF binding protein-3 in serum from children with Perthes’ disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
8
0

Year Published

2005
2005
2021
2021

Publication Types

Select...
4
4

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 15 publications
1
8
0
Order By: Relevance
“…IGFBP-3 was normal, which also agrees with some (Neidel et al 1993, Grasemann et al 1996 but not other (Matsumoto et al 1998) reports.…”
Section: Discussionsupporting
confidence: 80%
See 1 more Smart Citation
“…IGFBP-3 was normal, which also agrees with some (Neidel et al 1993, Grasemann et al 1996 but not other (Matsumoto et al 1998) reports.…”
Section: Discussionsupporting
confidence: 80%
“…The bioactivity of circulating IGF-I at target tissue level is, in turn, modulated by its main binding protein, IGFBP-3, and protease activity. There have been conflicting reports regarding circulating levels of IGF-I and IGFBP-3 in children with Perthes' disease (Neidel et al 1992a, b, 1993, Grasemann et al 1996, Matsumoto et al 1998). In addition to hormonal influences, bone growth may be influenced directly by mechanical factors (Golding 1994).…”
mentioning
confidence: 99%
“…In plasma, nearly all the IGF-1 is bound to specific binding proteins, which for IGF-1 is the IGF-binding protein 3 (IGFBP3). Decreased levels of IGFBP in children with LCPD have been seen but with normal levels of IGF-1 [90]. No abnormalities in IGF-1 or IGFBP concentrations have been encountered by others [68, 83, 91, 92] in children with LCPD.…”
Section: Resultsmentioning
confidence: 99%
“…18,19 These results conflict with another study, which reported normal IGF-1 binding protein levels. Thus, dysfunction in the IGF-1 pathway can potentially explain the delayed skeletal maturation, hyperactive behavior, and minor congenital abnormalities seen in the patients with LCPD.…”
Section: Abnormality In the Insulin-like Growth Factor-1 Pathwaymentioning
confidence: 62%